Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
72,922,597
-
Total 13F shares
-
49,357,693
-
Share change
-
+7,102,557
-
Total reported value
-
$327,711,484
-
Price per share
-
$6.64
-
Number of holders
-
109
-
Value change
-
+$52,680,502
-
Number of buys
-
76
-
Number of sells
-
21
Institutional Holders of Lexeo Therapeutics, Inc. - Common Stock (LXEO) as of Q3 2025
As of 30 Sep 2025,
Lexeo Therapeutics, Inc. - Common Stock (LXEO) was held by
109 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
49,357,693 shares.
The largest 10 holders included
JANUS HENDERSON GROUP PLC, Frazier Life Sciences Management, L.P., Balyasny Asset Management L.P., Affinity Asset Advisors, LLC, CITADEL ADVISORS LLC, Vestal Point Capital, LP, Woodline Partners LP, MILLENNIUM MANAGEMENT LLC, VANGUARD GROUP INC, and BlackRock, Inc..
This page lists
109
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.